ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Realigns Executive Leadership Team

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces September Investor Conference Participation

31 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

10 Aug 2023 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

26 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

11 May 2023 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

09 May 2023 06:00:02 By Nasdaq GlobeNewswire

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

25 Apr 2023 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

13 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

09 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

16 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

05 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12 Dec 2022 09:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Scott Garland to its Board of Directors

29 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

03 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

02 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

31 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

05 Oct 2022 07:01:00 By Nasdaq GlobeNewswire

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

21 Sep 2022 15:01:00 By Nasdaq GlobeNewswire